Double-monomer gradient ratio medical adhesive structure
By using a dual-monomer gradient ratio medical adhesive structure, the problems of insufficient curing speed and durability, as well as poor biocompatibility, of traditional medical adhesives in wound hemostasis are solved. This achieves immediate hemostasis and long-term closure of wounds, reduces the risk of infection, and promotes wound healing and biocompatibility.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-30
- Publication Date
- 2026-03-24
AI Technical Summary
Traditional medical adhesives have problems in wound hemostasis treatment, such as excessively fast curing speed but insufficient long-lasting adhesion and poor biocompatibility, leading to adhesive layer detachment and inflammatory reactions.
The medical adhesive employs a dual-monomer gradient ratio structure, comprising a surface rapid-curing component, an intermediate transition layer component, and a deep durable adhesive component. Through gradient mixing of α-cyanoacrylate n-butyl ester and n-octyl ester, combined with biocompatibility modification, antibacterial treatment, adhesion enhancement, flexibility adjustment, and biodegradation, it achieves rapid wound closure, durable adhesion, and biocompatibility.
It achieves immediate hemostasis and long-term closure of the wound, reduces the risk of infection, enhances adhesion stability and biocompatibility, promotes the wound healing process, and reduces adverse reactions and medical costs.
Smart Images
Figure CN121714746A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of medical adhesive technology, and in particular to a dual-monomer gradient ratio medical adhesive structure. Background Technology
[0002] Traditional medical adhesives present several problems in wound hemostasis. For example, some medical adhesives cure too quickly but lack sufficient long-lasting adhesion, making them prone to detachment when the wound is moved or subjected to external force, thus affecting hemostasis. Other medical adhesives have poor biocompatibility, potentially leading to adverse consequences such as inflammatory reactions in the surrounding tissues. Therefore, developing a medical adhesive that can quickly seal the surface of the wound, achieve long-lasting adhesion at deeper layers, and possess good biocompatibility is of significant practical importance. Summary of the Invention
[0003] This application provides a dual-monomer gradient ratio medical adhesive structure to improve the durability and biocompatibility of wound hemostasis.
[0004] This application provides a dual-monomer gradient ratio medical adhesive structure, comprising: a surface rapid-curing component, an intermediate transition layer component, and a deep durable adhesive component, wherein...
[0005] The surface rapid curing component uses high concentrations of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense film that seals the wound surface; after biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis and protection and prevents infection.
[0006] The intermediate transition layer component is used to achieve a smooth transition in curing and adhesion properties by gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators and crosslinking density adjustment, thereby promoting stable integration of the overall structure.
[0007] The deep, durable adhesive component utilizes a high-concentration layer of n-octyl ester to achieve durable adhesion. Through adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, deep adhesion stabilization is achieved.
[0008] In the above technical solution, by setting up a surface rapid curing component, an intermediate transition layer component, and a deep durable adhesive component, the surface rapid curing component uses a high concentration of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense adhesive film that seals the wound surface. After biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis protection and prevents infection. The intermediate transition layer component is used to achieve a smooth transition between curing and adhesion performance through a gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators, and crosslinking density adjustment, promoting stable fusion of the overall structure. The deep durable adhesive component uses a high-concentration n-octyl ester layer to achieve durable adhesion, and after adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, it achieves deep adhesion stability, thus improving the durability and biocompatibility of wound hemostasis.
[0009] In one specific implementation, the surface rapid curing component includes:
[0010] A high-concentration layer of α-cyanoacrylate is used to form a dense adhesive film through a polymerization reaction upon contact with the wound surface;
[0011] The rapid curing accelerator addition layer is used to add a rapid curing accelerator to reduce the activation energy of the polymerization reaction.
[0012] In one specific implementation, the surface rapid curing component includes:
[0013] The surface antibacterial component loading layer is used to load the continuously released antibacterial components and inhibit the growth and reproduction of bacteria around the wound.
[0014] In one specific implementation, the surface rapid curing component includes:
[0015] The surface adhesion enhancement layer is used to add adhesive polymers to enhance the adhesion between the adhesive film and the wound tissue.
[0016] In one possible implementation, the intermediate transition layer component includes:
[0017] A gradient mixture of α-cyanoacrylate n-butyl ester and n-octyl ester is used to achieve a smooth transition in curing speed and adhesion performance, avoiding stress concentration problems caused by abrupt changes in composition;
[0018] The transition layer is a flexibility adjustment layer used to add plasticizers, enabling the medical adhesive to adapt to the deformation of the wound when subjected to external forces.
[0019] In one possible implementation, the intermediate transition layer component includes:
[0020] The transition layer is a bioactive substance introduction layer, used to add bioactive substances to stimulate the proliferation and differentiation of wound cells.
[0021] In one possible implementation, the intermediate transition layer component includes:
[0022] The transition layer photoinitiator addition layer is used to add photoinitiators, regulate the curing degree and speed of the transition layer, and enable the transition layer to fuse with the surface and deep layers to form an overall stable cured structure.
[0023] In one possible implementation, the deep, durable adhesive assembly includes:
[0024] High-concentration n-octyl ester layer is used to form strong chemical bonds and physical intercalation between the deep layers and the wound tissue;
[0025] Deep adhesion promoting layer, used to enhance the adhesion of medical adhesives to deep tissues.
[0026] In one possible implementation, the deep, durable adhesive assembly includes:
[0027] A deep biodegradable conditioning layer is used to add biodegradable components, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions.
[0028] In one possible implementation, the deep, durable adhesive assembly includes:
[0029] The deep stress buffer layer is used to buffer stress through its own deformation when medical adhesive is subjected to external forces. Attached Figure Description
[0030] Figure 1 This is a schematic diagram of the structure of the dual-monomer gradient ratio medical adhesive provided in the embodiments of this application.
[0031] Among them, 1-surface rapid curing component, 2-intermediate transition layer component, and 3-deep durable adhesive component. Detailed Implementation
[0032] The present application will now be described in further detail with reference to the accompanying drawings and embodiments. Through these descriptions, the features and advantages of the present application will become clearer and more apparent.
[0033] The term “exemplary” as used herein means “serving as an example, embodiment, or illustration.” Any embodiment illustrated herein as “exemplary” is not necessarily to be construed as superior to or better than other embodiments. Although various aspects of embodiments are shown in the accompanying drawings, the drawings are not necessarily drawn to scale unless specifically indicated otherwise.
[0034] Furthermore, the technical features involved in the different embodiments of this application described below can be combined with each other as long as they do not conflict with each other.
[0035] To facilitate understanding of the dual-monomer gradient ratio medical adhesive structure provided in this application embodiment, its application scenario will be explained first. The dual-monomer gradient ratio medical adhesive structure provided in this application embodiment is used to improve the durability and biocompatibility of wound hemostasis. Traditional medical adhesives have some problems in wound hemostasis. For example, some medical adhesives cure too quickly but lack sufficient long-lasting adhesion, leading to easy detachment of the adhesive layer when the wound is active or subjected to external force, affecting the hemostatic effect; some medical adhesives also have poor biocompatibility, which may cause adverse consequences such as inflammatory reactions in the surrounding tissues. Therefore, developing a medical adhesive that can quickly seal the wound surface, achieve long-lasting adhesion in deeper layers, and has good biocompatibility is of significant practical importance. To this end, this application embodiment provides a dual-monomer gradient ratio medical adhesive structure to improve the durability and biocompatibility of wound hemostasis. The following detailed description, in conjunction with specific accompanying drawings, illustrates this concept.
[0036] refer to Figure 1 , Figure 1 This is a schematic diagram of the structure of the dual-monomer gradient ratio medical adhesive provided in the embodiments of this application.
[0037] exist Figure 1 This application provides a dual-monomer gradient ratio medical adhesive structure, comprising: a surface rapid-curing component 1, an intermediate transition layer component 2, and a deep, durable adhesive component 3, wherein...
[0038] The surface rapid curing component uses high concentrations of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense film that seals the wound surface; after biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis and protection and prevents infection.
[0039] The intermediate transition layer component is used to achieve a smooth transition in curing and adhesion properties by gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators and crosslinking density adjustment, thereby promoting stable integration of the overall structure.
[0040] The deep, durable adhesive component utilizes a high-concentration layer of n-octyl ester to achieve durable adhesion. Through adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, deep adhesion stabilization is achieved.
[0041] In the above technical solution, by setting up a surface rapid curing component, an intermediate transition layer component, and a deep durable adhesive component, the surface rapid curing component uses a high concentration of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense adhesive film that seals the wound surface. After biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis protection and prevents infection. The intermediate transition layer component is used to achieve a smooth transition between curing and adhesion performance through a gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators, and crosslinking density adjustment, promoting stable fusion of the overall structure. The deep durable adhesive component uses a high-concentration n-octyl ester layer to achieve durable adhesion, and after adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, it achieves deep adhesion stability, thus improving the durability and biocompatibility of wound hemostasis.
[0042] Specifically, the beneficial effects include:
[0043] Significant immediate hemostasis and infection prevention effects: The rapid-curing surface component uses a high concentration of n-butyl α-cyanoacrylate and an accelerator, enabling a rapid polymerization reaction that quickly forms a dense adhesive film on the wound surface. This characteristic allows the medical adhesive to effectively seal the wound upon contact, preventing further bleeding and achieving immediate hemostasis, buying valuable time for subsequent treatment. Simultaneously, the surface undergoes biocompatibility modification, antibacterial treatment, and adhesion enhancement, which not only strengthens the adhesion between the adhesive film and wound tissue, ensuring the durability of the hemostatic effect, but also effectively inhibits bacterial growth, prevents wound infection, reduces the risk of complications caused by infection, and promotes faster and better wound healing.
[0044] Smooth transition in adhesion performance and stable integration of the overall structure: The intermediate transition layer component cleverly achieves a smooth transition in curing and adhesion performance through a gradient mixing of α-cyanoacrylate n-butyl ester and n-octyl ester. This gradient mixing design avoids the problem of interfacial stress concentration caused by excessive differences in the properties of the two monomers, allowing the medical adhesive to naturally fuse between different layers to form a whole. By combining flexibility, bioactive substances, photoinitiators, and crosslinking density adjustment, the performance of the intermediate transition layer is further optimized, enabling it to adapt to the minor deformations of the wound during the healing process while ensuring sufficient adhesive strength. This provides a strong guarantee for the stable integration of the overall structure and effectively prevents phenomena such as delamination and detachment of the medical adhesive during use.
[0045] Deep and durable adhesion to meet long-term treatment needs: The deep and durable adhesive component utilizes a high-concentration layer of n-octyl ester to achieve long-lasting adhesion to deep wound layers. Through adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, this component can maintain good adhesion to tissue while rationally adjusting its biodegradation rate according to the wound healing process. This avoids adhesion failure due to excessively rapid degradation or hindering normal tissue repair due to excessively slow degradation. Furthermore, the stress buffering design effectively disperses stress generated during wound activity, reducing damage to the adhesion site, while excellent tissue compatibility ensures that long-term use of the medical adhesive in deep tissues will not cause rejection reactions, providing stable and reliable support for long-term wound healing.
[0046] Enhancing Wound Hemostasis Durability and Biocompatibility: Combining the advantages of its three-layer components, this medical adhesive structure significantly improves the durability of wound hemostasis. The rapid hemostasis of the surface layer, combined with the effective adhesion of the middle and deep layers, forms a comprehensive, multi-layered hemostatic protection system that maintains the wound's closure for an extended period, reducing the risk of bleeding. Simultaneously, biocompatibility is fully considered in the design and processing of each component. From material selection to process optimization, efforts are made to minimize irritation and damage to human tissues, creating a favorable physiological environment for wound healing, thus improving patient recovery quality and reducing medical costs.
[0047] In one specific implementation, the surface rapid curing component includes:
[0048] A high-concentration layer of α-cyanoacrylate is used to form a dense adhesive film through a polymerization reaction upon contact with the wound surface;
[0049] The rapid curing accelerator addition layer is used to add a rapid curing accelerator to reduce the activation energy of the polymerization reaction.
[0050] In the above technical solution, the high-concentration layer of α-cyanoacrylate allows for rapid polymerization upon contact with the wound. This rapid reaction mechanism enables the formation of a dense film within a very short time, effectively sealing the wound, preventing blood outflow, and achieving immediate hemostasis. This characteristic is particularly important for acute traumatic bleeding, as it quickly controls the bleeding, buys crucial time for subsequent medical treatment, and reduces the risk of excessive blood loss. The addition of a rapid-curing accelerator layer lowers the activation energy of the polymerization reaction by adding a specific rapid-curing accelerator. This means that under relatively mild conditions, the polymerization reaction can proceed more quickly and fully. This not only further accelerates the film formation speed, making the hemostatic effect more immediate, but also ensures a more stable and reliable film quality. The resulting film has better density and strength, and can more effectively resist interference from external factors, such as slight friction and pressure, preventing film rupture and rebleeding. This layered design also ensures that each layer has a clear function and works synergistically. The high-concentration layer provides the basic reactants, while the accelerator layer optimizes the reaction conditions. The two work together to ensure rapid hemostasis while improving the performance stability of the entire surface rapid curing component. This provides a reliable immediate protective barrier for the wound, which helps with subsequent wound healing and recovery, and enhances the effectiveness and safety of the medical adhesive.
[0051] In one specific implementation, the surface rapid curing component includes:
[0052] The surface antibacterial component loading layer is used to load the continuously released antibacterial components and inhibit the growth and reproduction of bacteria around the wound.
[0053] In the aforementioned technical solution, the surface antibacterial loading layer can carry a continuously released antibacterial component, creating a long-lasting antibacterial defense for the wound. In the early stages of wound formation, the surrounding environment is complex and prone to bacterial growth. These bacteria not only delay wound healing but can also cause infection, leading to more serious complications. This loading layer, by continuously releasing antibacterial components, can maintain an effective antibacterial concentration around the wound for a longer period, continuously inhibiting bacterial growth and reproduction, effectively reducing the risk of wound infection, and creating a relatively clean and safe environment for wound healing. The continuously released antibacterial mechanism avoids the problems of short-lived and uneven antibacterial effects that may occur with traditional antibacterial methods. It can function stably and persistently, without the need for frequent replacement or replenishment of antibacterial substances, reducing the complexity of medical procedures and minimizing patient pain and the possibility of secondary injury caused by frequent procedures. Furthermore, this loading layer works synergistically with other parts of the surface rapid-curing component to achieve rapid hemostasis and wound closure while also providing antibacterial function, making the medical adhesive more comprehensive in its functionality. It can control bleeding in a timely manner and prevent infection, greatly improving the effectiveness and success rate of wound treatment, helping patients recover their health faster and shortening the recovery period.
[0054] In one specific implementation, the surface rapid curing component includes:
[0055] The surface adhesion enhancement layer is used to add adhesive polymers to enhance the adhesion between the adhesive film and the wound tissue.
[0056] In the above technical solution, the surface adhesion enhancement layer, by adding adhesive polymers, significantly enhances the adhesion between the adhesive film and the wound tissue. During the wound hemostasis phase, this strong adhesion allows the adhesive film to quickly and tightly adhere to the wound, forming a stable and reliable sealing layer that effectively blocks blood flow and achieves rapid hemostasis. Compared with ordinary medical adhesives, it greatly reduces the risk of secondary bleeding caused by poor adhesion, buying valuable time for subsequent medical treatment. During wound healing, the stable adhesion allows the adhesive film to better resist interference from external factors. In daily activities, the body inevitably experiences friction and collisions; good adhesion ensures that the adhesive film will not easily shift or detach, continuously providing protection for the wound and maintaining a relatively stable healing environment. In addition, the tight binding of the adhesive polymers with the wound tissue promotes cell adhesion and growth on the adhesive film surface, which is beneficial for tissue repair and regeneration. It acts like a "bridge," guiding the orderly migration and proliferation of cells around the wound, accelerating the wound healing process and shortening the recovery period. Moreover, this adhesion-enhancing design requires no complicated procedures, does not increase patient discomfort, has high clinical applicability and operability, and can effectively improve patients' treatment experience and rehabilitation outcomes.
[0057] In one possible implementation, the intermediate transition layer component includes:
[0058] A gradient mixture of α-cyanoacrylate n-butyl ester and n-octyl ester is used to achieve a smooth transition in curing speed and adhesion performance, avoiding stress concentration problems caused by abrupt changes in composition;
[0059] The transition layer is a flexibility adjustment layer used to add plasticizers, enabling the medical adhesive to adapt to the deformation of the wound when subjected to external forces.
[0060] In the aforementioned technical solution, the design of the gradient mixing layer of α-cyanoacrylate n-butyl ester and n-octyl ester is ingenious. This gradient mixing method achieves a smooth transition in curing speed and adhesive performance. During the use of medical adhesives, abrupt changes in the composition and properties of different layers can easily lead to stress concentration at the interface, resulting in problems such as adhesive layer cracking and detachment, affecting the adhesive effect and wound healing. This gradient mixing layer effectively avoids this drawback, allowing the medical adhesive to gradually change its curing speed from the surface to the deeper layers, with adhesive performance also gradually increasing. The layers can naturally fuse together, forming a stable and reliable overall structure, providing durable and strong adhesive protection for the wound. The transition layer, a flexibility adjustment layer, imparts good flexibility to the medical adhesive through the addition of plasticizers. In practical applications, wounds often deform to varying degrees due to body activity. If the medical adhesive lacks sufficient flexibility, it is prone to breakage during deformation, losing its adhesive effect. This regulating layer allows the medical adhesive to adapt to the deformation of the wound, maintaining its integrity and adhesive properties under external forces. It will not be damaged by the slight movement of the wound, further enhancing the practicality and reliability of the medical adhesive. This helps the wound heal better in a dynamic environment and improves the overall treatment effect.
[0061] In one possible implementation, the intermediate transition layer component includes:
[0062] The transition layer is a bioactive substance introduction layer, used to add bioactive substances to stimulate the proliferation and differentiation of wound cells.
[0063] In the above technical solution, the addition of bioactive substances allows the introduction layer to directly act on wound cells. These bioactive substances act like "catalysts" for cell growth, precisely stimulating the proliferation and differentiation of wound cells. In the early stages of wound healing, they quickly awaken dormant cells, activating them, increasing cell numbers, and providing sufficient "raw materials" for wound repair. Simultaneously, they guide cells to differentiate into specific functional directions, such as promoting fibroblasts to produce more collagen and accelerating granulation tissue formation, thus building a solid structural foundation for wound healing. Compared to traditional medical adhesives, this method of introducing bioactive substances transforms medical adhesives from simple physical bonding materials into tools that actively promote wound repair. It can accelerate the wound healing process and shorten the recovery period by working at the cellular level. Moreover, bioactive substances typically have good biocompatibility, do not adversely stimulate wound tissue, and reduce the risk of rejection and complications.
[0064] In one possible implementation, the intermediate transition layer component includes:
[0065] The transition layer photoinitiator addition layer is used to add photoinitiators, regulate the curing degree and speed of the transition layer, and enable the transition layer to fuse with the surface and deep layers to form an overall stable cured structure.
[0066] In the above technical solution, the addition of a photoinitiator allows for precise control of the curing degree and speed of the transition layer. During the use of medical adhesives, if the curing conditions of different layers (surface, transition layer, and deep layer) are not coordinated, it can easily lead to loose bonding between layers, resulting in delamination, cracking, and other problems, affecting the overall structural stability. The photoinitiator, however, can flexibly control the curing process of the transition layer according to actual needs, matching its curing speed with that of the surface and deep layers, achieving seamless fusion and forming a stable, overall cured structure that provides durable and reliable closure and protection for the wound. This precise control also gives the medical adhesive better adaptability. Under different wound environments and treatment requirements, the curing characteristics of the transition layer can be changed by adjusting light parameters (such as light intensity and time) to meet diverse clinical needs. For example, for more complex, irregularly shaped wounds, precise local curing can be achieved, ensuring perfect adhesion between the medical adhesive and the wound.
[0067] In one possible implementation, the deep, durable adhesive assembly includes:
[0068] High-concentration n-octyl ester layer is used to form strong chemical bonds and physical intercalation between the deep layers and the wound tissue;
[0069] Deep adhesion promoting layer, used to enhance the adhesion of medical adhesives to deep tissues.
[0070] In the aforementioned technical solution, the high-concentration n-octyl ester layer enables the deep layer to form strong chemical bonds and physical interlocking with the wound tissue. The formation of chemical bonds establishes a tight molecular connection between the medical adhesive and the tissue. This connection possesses high strength and stability, effectively resisting external tensile and shear forces and preventing the medical adhesive from detaching from the wound during use. Physical interlocking further enhances this adhesive effect. By penetrating deep into the tissue interstices and intertwining with the tissue, the medical adhesive acts like an "anchor" to the wound, significantly improving the strength of the adhesion and providing long-term, reliable closure protection for the wound, especially suitable for wounds requiring prolonged adhesion. The deep adhesion-promoting layer plays a crucial role in enhancing the adhesion between the medical adhesive and deep tissue. It optimizes the interfacial properties between the medical adhesive and tissue, reducing interfacial energy and making them easier to bond tightly. Simultaneously, this layer may contain components that promote the release of surface-active substances or alter the surface charge distribution of the tissue, further enhancing the medical adhesive's adsorption capacity to the tissue. The synergistic effect of the two not only ensures the long-lasting adhesion of the medical adhesive to the wound, but also adapts to wound tissues of different depths and types, reducing the risk of adhesion failure caused by wound activity or external factors, creating a stable environment for wound healing, helping to shorten the recovery period and improve treatment outcomes.
[0071] In one possible implementation, the deep, durable adhesive assembly includes:
[0072] A deep biodegradable conditioning layer is used to add biodegradable components, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions.
[0073] In the aforementioned technical solution, the addition of biodegradable components gives the medical adhesive the ability to self-remove. After completing its crucial tasks of hemostasis and adhesion, the medical adhesive does not remain in the body for extended periods but is gradually absorbed over time. This characteristic effectively avoids a series of problems that can arise from the long-term residue of traditional medical adhesives, such as local tissue inflammation and the formation of foreign body granulomas, reducing the risk of postoperative complications and alleviating the patient's physical burden. From a treatment perspective, the biodegradable nature eliminates the need for secondary surgery to remove the medical adhesive, reducing patient suffering and medical costs. Patients can achieve natural wound healing without undergoing additional invasive procedures, significantly improving the treatment experience. Furthermore, biodegradable components typically have good biocompatibility, coexisting harmoniously with human tissues without causing adverse stimulation or damage to surrounding normal tissues. Moreover, the degradation rate can be controlled according to actual needs. By adjusting the component ratio or adding specific regulators, the medical adhesive can be degraded within a suitable time range, ensuring that it plays a sufficient role in the hemostasis and adhesion stages, and can be absorbed by the human body in a timely and orderly manner, creating favorable conditions for wound healing.
[0074] In one possible implementation, the deep, durable adhesive assembly includes:
[0075] The deep stress buffer layer is used to buffer stress through its own deformation when medical adhesive is subjected to external forces.
[0076] In the aforementioned technical solution, when medical adhesive is subjected to external forces, such as pulling or collisions caused by physical activity, without an effective buffering mechanism, the stress will directly concentrate at the bonding interface between the medical adhesive and the wound tissue. This stress concentration can easily lead to cracking of the adhesive layer and separation from the tissue, thereby causing the hemostasis and adhesion functions to fail, affecting wound healing, and even potentially causing serious problems such as secondary bleeding. The deep stress buffer layer, however, can buffer stress through its own deformation. It acts like a "shock absorber," deforming itself when subjected to external forces to disperse the concentrated stress and reduce the stress intensity at the bonding interface. In this way, the adhesion between the medical adhesive and the wound tissue remains stable and is not easily damaged by external forces, ensuring the durability of hemostasis and adhesion effects. Furthermore, this buffer layer can adapt to the minute movements of the tissue surrounding the wound. Human tissue is not completely static and undergoes certain physiological activities during daily life. The buffer layer can adjust accordingly with the minute deformations of the tissue, further reducing the impact of stress generated by tissue activity on the adhesive performance of the medical adhesive. This not only helps wounds heal better in a dynamic environment, but also improves patient comfort and reduces discomfort caused by stress mismatch between medical adhesive and tissue.
[0077] In one specific implementation scheme, the dual-monomer gradient ratio medical adhesive structure includes: a surface rapid-curing component, an intermediate transition layer component, and a deep durable adhesive component, wherein,
[0078] The surface rapid curing component uses high concentrations of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense film that seals the wound surface; after biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis and protection and prevents infection.
[0079] The intermediate transition layer component is used to achieve a smooth transition in curing and adhesion properties by gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators and crosslinking density adjustment, thereby promoting stable integration of the overall structure.
[0080] The deep, durable adhesive component utilizes a high-concentration layer of n-octyl ester to achieve durable adhesion. Through adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, deep adhesion stabilization is achieved.
[0081] The surface rapid curing component includes:
[0082] A high-concentration layer of α-cyanoacrylate is used to form a dense adhesive film through a polymerization reaction upon contact with the wound surface;
[0083] The rapid curing accelerator addition layer is used to add rapid curing accelerators and reduce the activation energy of the polymerization reaction;
[0084] A biocompatible surface modification layer is used to reduce the irritation of the membrane to the surrounding tissues of the wound.
[0085] The surface antibacterial component loading layer is used to load the continuously released antibacterial components and inhibit the growth and reproduction of bacteria around the wound.
[0086] The surface adhesion enhancement layer is used to add adhesive polymers to enhance the adhesion between the adhesive film and the wound tissue.
[0087] The intermediate transition layer component includes:
[0088] A gradient mixture of α-cyanoacrylate n-butyl ester and n-octyl ester is used to achieve a smooth transition in curing speed and adhesion performance, avoiding stress concentration problems caused by abrupt changes in composition.
[0089] The transition layer is a flexibility adjustment layer used to add plasticizers, enabling the medical adhesive to adapt to the deformation of the wound when subjected to external forces.
[0090] The transition layer is a bioactive substance introduction layer, used to add bioactive substances to stimulate the proliferation and differentiation of wound cells.
[0091] The transition layer photoinitiator addition layer is used to add photoinitiators, regulate the curing degree and speed of the transition layer, and enable the transition layer to fuse with the surface and deep layers to form an overall stable cured structure.
[0092] The transition layer crosslinking density adjustment layer is used to add crosslinking agents and adjust the crosslinking density of the transition layer.
[0093] The deep, durable adhesive assembly includes:
[0094] High-concentration octyl ester layer is used to form strong chemical bonds and physical intercalation between the deep layers and the wound tissue.
[0095] Deep adhesion promoting layer, used to enhance the adhesion of medical adhesives to deep tissues.
[0096] A deep biodegradable conditioning layer is used to add biodegradable components, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions.
[0097] The deep stress buffer layer is used to buffer stress through its own deformation when medical adhesive is subjected to external forces.
[0098] A deep tissue compatibility optimization layer is used to promote the integration of medical adhesives with deep tissues.
[0099] In this embodiment, the rapid surface curing component provides immediate hemostasis and multiple layers of protection. Utilizing a high concentration of α-cyanoacrylate (n-butyl ester) and an accelerator, it undergoes a polymerization reaction upon contact with the wound surface, rapidly forming a dense film to seal the wound surface and achieve immediate hemostasis, buying valuable time for subsequent treatment. The rapid curing accelerator layer lowers the activation energy of the polymerization reaction, accelerating the curing process and further improving hemostasis efficiency. The surface biocompatibility modification layer reduces the film's irritation to surrounding tissues, minimizing inflammation and improving patient comfort. The surface antibacterial loading layer can carry continuously released antibacterial components, effectively inhibiting bacterial growth and reproduction around the wound, preventing infection, and reducing the risk of complications. The surface adhesion enhancement layer adds adhesive polymers, enhancing the adhesion between the film and wound tissue, ensuring stable adhesion of the film to the wound surface, preventing detachment, and providing a reliable protective barrier for the wound.
[0100] Intermediate Transition Layer Components: Smooth Transition and Performance Optimization
[0101] The intermediate transition layer assembly achieves a smooth transition in curing speed and adhesive performance through a gradient mixing of α-cyanoacrylate (n-butyl acrylate) and octyl acrylate, avoiding stress concentration problems caused by abrupt changes in composition. This allows the layers of the medical adhesive to naturally fuse, forming a stable and reliable overall structure. The transition layer flexibility adjustment layer contains plasticizers, enabling the medical adhesive to adapt to wound deformation under external forces, reducing adhesive layer cracking or detachment caused by wound activity and maintaining the durability of the adhesive effect. The transition layer bioactive substance introduction layer contains bioactive substances that stimulate the proliferation and differentiation of wound cells, accelerate granulation tissue formation, and promote wound healing. The transition layer photoinitiator addition layer contains photoinitiators that regulate the curing degree and speed of the transition layer, allowing it to better fuse with the surface and deeper layers, forming a stable overall cured structure. The transition layer crosslinking density adjustment layer contains crosslinking agents to adjust the crosslinking density of the transition layer, further optimizing the physical properties of the medical adhesive and enhancing its stability and durability.
[0102] Deeply bonded components: long-lasting adhesion and safe absorption
[0103] The high-concentration n-octyl ester layer of the deep, durable adhesive component enables the formation of strong chemical bonds and physical integration between the deep adhesive layer and the wound tissue, achieving durable adhesion and providing long-term, stable closure protection for the wound. The deep adhesion-promoting layer enhances the adhesion between the medical adhesive and deep tissues, ensuring that the adhesive remains tightly adhered to the tissue under various physiological activities and external forces. The deep biodegradable regulating layer contains biodegradable components, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostasis and adhesion functions. This avoids problems such as local tissue inflammation and foreign body granuloma formation that may be caused by long-term residue of traditional medical adhesives, reducing the risk of secondary surgical removal and patient suffering. The deep stress-buffering layer can buffer stress through its own deformation when the medical adhesive is subjected to external forces, protecting the adhesive interface and preventing cracking. The deep tissue compatibility optimization layer promotes the integration of the medical adhesive with deep tissues, further improving the biocompatibility and therapeutic efficacy of the medical adhesive.
[0104] In one specific implementation scheme, the dual-monomer gradient ratio medical adhesive structure includes:
[0105] 1. Surface fast-curing components, including:
[0106] The high-concentration layer of α-cyanoacrylate n-butyl ester has a high content of α-cyanoacrylate n-butyl ester. Utilizing its short molecular chain and high reactivity, it can rapidly polymerize upon contact with the wound surface, quickly forming a dense film to achieve rapid sealing of the wound surface and effectively prevent blood outflow.
[0107] A rapid-curing accelerator layer is added to the high-concentration α-butyl cyanoacrylate layer, incorporating specific rapid-curing accelerators, such as organic bases. These accelerators lower the activation energy of the polymerization reaction, further accelerating the polymerization rate and ensuring surface curing is completed in a very short time, providing immediate hemostatic protection for the wound.
[0108] The surface biocompatibility modification layer, achieved by introducing biocompatible substances such as polyethylene glycol (PEG) to the surface, reduces the irritation of the adhesive film to the surrounding tissues and minimizes inflammatory responses. PEG molecules possess good flexibility and hydrophilicity, enabling them to form a protective film on the adhesive film surface and improve tissue compatibility.
[0109] The surface antibacterial loading layer carries an appropriate amount of antibacterial components, such as silver ions or quaternary ammonium compounds. These antibacterial components can be continuously released after the surface layer solidifies, inhibiting the growth and reproduction of bacteria around the wound, preventing wound infection, and creating a favorable environment for wound healing.
[0110] The surface adhesion enhancement layer incorporates adhesive polymers such as chitosan. Chitosan possesses excellent bioadhesive properties, enhancing the adhesion between the adhesive film and wound tissue, resulting in a more secure and less prone-to-detachment surface.
[0111] 2. Intermediate transition layer components, including:
[0112] A gradient mixture of α-cyanoacrylate (n-butyl acrylate) and n-octyl acrylate is used, in which the contents of α-cyanoacrylate and n-octyl acrylate change in a gradient, gradually transitioning from a high concentration of α-cyanoacrylate near the surface to a higher concentration of n-octyl acrylate near the depth. This gradient mixing structure enables a smooth transition in curing speed and adhesion performance, avoiding problems such as stress concentration caused by abrupt changes in composition.
[0113] The transition layer is a flexibility-adjusting layer, incorporating plasticizers such as dibutyl phthalate. These plasticizers can intercalate between polymer molecular chains, increasing chain fluidity and improving the flexibility of the transition layer. This allows the medical adhesive to better adapt to wound deformation under external forces, reducing the risk of adhesive layer cracking.
[0114] The transition layer is a bioactive substance introduction layer, which introduces bioactive substances that promote wound healing, such as growth factors (e.g., epidermal growth factor, fibroblast growth factor, etc.). These growth factors can be slowly released in the transition layer, stimulating the proliferation and differentiation of wound cells and accelerating the wound healing process.
[0115] A photoinitiator-added transition layer is added, with an appropriate amount of photoinitiator, such as benzophenone. In some cases, the curing degree and speed of the transition layer can be further controlled by light irradiation, allowing the transition layer to better integrate with the surface and deeper layers, forming a stable overall cured structure.
[0116] The transition layer crosslinking density adjustment layer is achieved by adding crosslinking agents, such as multifunctional acrylate compounds, to regulate the crosslinking density of the transition layer. An appropriate crosslinking density can improve the mechanical properties and stability of the transition layer while ensuring it retains a certain degree of flexibility to accommodate the physiological activities of the wound.
[0117] 3. Deeply bonded components, including:
[0118] The high-concentration n-octyl ester layer contains a high amount of n-octyl ester. While the n-octyl ester molecular chain is relatively long and its reactivity is relatively low, the polymer formed after curing exhibits good flexibility and durable adhesion. It can form strong chemical bonds and physical intercalation with the wound tissue deep within the wound, achieving a long-lasting adhesive effect and ensuring that it does not easily detach when the wound is active or subjected to significant external forces.
[0119] A deep adhesion-enhancing layer is added, incorporating substances that promote adhesion to tissues, such as dopamine compounds. Dopamine possesses unique adhesive properties, forming a stable adhesive layer on the tissue surface, enhancing the adhesion between medical adhesives and deeper tissues, and improving the durability of the bond.
[0120] The deep biodegradable conditioning layer introduces biodegradable components, such as polylactic acid-glycolic acid copolymer (PLGA). PLGA can gradually degrade in the body, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions, reducing residues in the body. At the same time, its degradation products are harmless to the human body and have good biocompatibility.
[0121] A deep stress buffer layer is added, incorporating microspheres or fibrous materials with cushioning properties, such as polymethyl methacrylate (PMMA) microspheres. These microspheres or fibers can be distributed deep within the layer, and when the medical adhesive is subjected to external forces, they can buffer the stress through their own deformation, preventing stress concentration that could lead to adhesive layer breakage, thereby improving the stability of the deep adhesion.
[0122] The deep tissue compatibility optimization layer adjusts the chemical composition and structure of the deep tissues to make them more compatible with the biochemical environment of the deep wound tissues. For example, introducing substances similar to the components of the extracellular matrix, such as collagen fragments, promotes the integration of medical adhesives with deep tissues, further improving biocompatibility and adhesion.
[0123] In this embodiment, the beneficial effects include:
[0124] 1. Significant Layered Curing Effect: By adjusting the molecular chain length ratio of α-butyl cyanoacrylate and octyl cyanoacrylate, a gradient curing layer structure was designed to achieve a layered curing effect from rapid surface sealing to deep, durable adhesion. Rapid surface curing quickly stops blood flow, providing immediate hemostatic protection for the wound; deep, durable adhesion ensures that the medical adhesive is not easily detached when the wound is active or subjected to significant external force, improving the durability of wound hemostasis.
[0125] 2. Excellent biocompatibility: Various biocompatible substances, such as polyethylene glycol, growth factors, and dopamine compounds, are introduced into the various components of the medical adhesive, and biodegradation regulation is implemented. These measures effectively reduce the irritation of the medical adhesive to the surrounding tissues of the wound, reduce the occurrence of inflammatory reactions, and allow the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions, reducing residues in the body and demonstrating excellent biocompatibility.
[0126] 3. Diverse Functions: The medical adhesive of this invention not only has hemostatic and adhesive functions, but also possesses multiple functions such as antibacterial properties and promoting wound healing. By loading antibacterial components and introducing bioactive substances, it can effectively prevent wound infection, accelerate the wound healing process, and provide a more comprehensive solution for wound treatment.
[0127] Those skilled in the art will know that this application can be implemented as a system, method, or computer program product.
[0128] Therefore, this disclosure can be implemented in the following forms: it can be entirely hardware, entirely software (including firmware, resident software, microcode, etc.), or a combination of hardware and software, generally referred to herein as a "circuit," "module," or "system." Furthermore, in some embodiments, this application can also be implemented as a computer program product in one or more computer-readable media, the computer-readable media containing computer-readable program code.
[0129] Any combination of one or more computer-readable media may be used. A computer-readable medium can be a computer-readable signal medium or a computer-readable storage medium. A computer-readable storage medium can be, for example, but not limited to, an electrical, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, or device, or any combination thereof. More specific examples (a non-exhaustive list) of computer-readable storage media include: an electrical connection having one or more wires, a portable computer disk, a hard disk, random access memory (RAM), read-only memory (ROM), erasable programmable read-only memory (EPROM or flash memory), optical fiber, portable compact disk read-only memory (CD-ROM), optical storage device, magnetic storage device, or any suitable combination thereof. In this document, a computer-readable storage medium can be any tangible medium that contains or stores a program that can be used by or in connection with an instruction execution system, apparatus, or device.
[0130] Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions, and variations to the above embodiments within the scope of this application. Based on this, various substitutions and improvements can be made to this application, all of which fall within the protection scope of this application.
Claims
1. A medical adhesive structure with dual monomer gradient ratios, characterized in that, include: The components include a surface-curing fast-curing layer, an intermediate transition layer, and a deep, durable adhesive layer. The surface rapid curing component uses high concentrations of n-butyl α-cyanoacrylate and an accelerator for rapid polymerization to form a dense film that seals the wound surface; after biocompatibility modification, antibacterial and adhesion enhancement treatments, it provides immediate hemostasis and protection and prevents infection. The intermediate transition layer component is used to achieve a smooth transition in curing and adhesion properties by gradient mixing of n-butyl α-cyanoacrylate and n-octyl ester, combined with flexibility, bioactive substances, photoinitiators and crosslinking density adjustment, thereby promoting stable integration of the overall structure. The deep, durable adhesive component utilizes a high-concentration layer of n-octyl ester to achieve durable adhesion. Through adhesion promotion, biodegradation regulation, stress buffering, and tissue compatibility optimization treatments, deep adhesion stabilization is achieved.
2. The dual-monomer gradient ratio medical adhesive structure according to claim 1, characterized in that, The surface rapid curing component includes: A high-concentration layer of α-cyanoacrylate is used to form a dense adhesive film through a polymerization reaction upon contact with the wound surface; The rapid curing accelerator addition layer is used to add a rapid curing accelerator to reduce the activation energy of the polymerization reaction.
3. The dual-monomer gradient ratio medical adhesive structure according to claim 2, characterized in that, The surface rapid curing component includes: The surface antibacterial component loading layer is used to load the continuously released antibacterial components and inhibit the growth and reproduction of bacteria around the wound.
4. The dual-monomer gradient ratio medical adhesive structure according to claim 3, characterized in that, The surface rapid curing component includes: The surface adhesion enhancement layer is used to add adhesive polymers to enhance the adhesion between the adhesive film and the wound tissue.
5. The dual-monomer gradient ratio medical adhesive structure according to claim 4, characterized in that, The intermediate transition layer component includes: A gradient mixture of α-cyanoacrylate n-butyl ester and n-octyl ester is used to achieve a smooth transition in curing speed and adhesion performance, avoiding stress concentration problems caused by abrupt changes in composition; The transition layer is a flexibility adjustment layer used to add plasticizers, enabling the medical adhesive to adapt to the deformation of the wound when subjected to external forces.
6. The dual-monomer gradient ratio medical adhesive structure according to claim 5, characterized in that, The intermediate transition layer component includes: The transition layer is a bioactive substance introduction layer, used to add bioactive substances to stimulate the proliferation and differentiation of wound cells.
7. The dual-monomer gradient ratio medical adhesive structure according to claim 6, characterized in that, The intermediate transition layer component includes: The transition layer photoinitiator addition layer is used to add photoinitiators, regulate the curing degree and speed of the transition layer, and enable the transition layer to fuse with the surface and deep layers to form an overall stable cured structure.
8. The dual-monomer gradient ratio medical adhesive structure according to claim 7, characterized in that, The deep, durable adhesive assembly includes: High-concentration n-octyl ester layer is used to form strong chemical bonds and physical intercalation between the deep layers and the wound tissue; Deep adhesion promoting layer, used to enhance the adhesion of medical adhesives to deep tissues.
9. The dual-monomer gradient ratio medical adhesive structure according to claim 8, characterized in that, The deep, durable adhesive assembly includes: A deep biodegradable conditioning layer is used to add biodegradable components, allowing the medical adhesive to be gradually absorbed by the body after completing its hemostatic and adhesive functions.
10. The dual-monomer gradient ratio medical adhesive structure according to claim 9, characterized in that, The deep, durable adhesive assembly includes: The deep stress buffer layer is used to buffer stress through its own deformation when medical adhesive is subjected to external forces.